| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-09-29 | solithromycin | NASH (non-alcoholic steatohepatitis) | 2 | Cempra (USA - NC) | Hepatic diseases - Liver diseases |
| 2016-09-29 | ponesimod and Tecfidera® (dimethyl fumarate) | relapsing multiple sclerosis (RMS) | 3 | Actelion (Switzerland) | Neurodegenerative diseases |
| 2016-09-29 | evofosfamide (TH-302) | advanced soft tissue sarcoma | 3 | Merck Serono, a Merck KGaA company (Germany) Threshold Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2016-09-29 | evofosfamide (TH-302) | patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma | 3 | Merck Serono, a Merck KGaA company (Germany) Threshold Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2016-09-29 | maribavir | cytomegalovirus infections | 3 | Shire (UK - USA) | Infectious diseases |
| 2016-09-29 | maribavir | cytomegalovirus infections | 3 | Shire (UK - USA) | Infectious diseases |
| 2016-09-29 | tarloxotinib (TH-4000) | patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR tyrosine kinase inhibitor and are progressing on treatment, but have not acquired the T790M resistance mutation |
2 | Threshold Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2016-09-29 | DCVax®-Direct | solid tumors | 1-2 | Northwest Biotherapeutics (USA - MD) | Cancer - Oncology |
| 2016-09-29 | QGC001 | hypertension | 2a | Quantum Genomics (France) | Cardiovascular diseases |
| 2016-09-29 | tarloxotinib (TH-4000) | recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS) | 2 | Threshold Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2016-09-29 | mazindol | Attention Deficit Hyperactivity Disorder (ADHD) | 2 | NLS Pharma (Switzerland) | CNS diseases - Mental diseases - Neurological diseases |
| 2016-09-29 | TH-3424 | 1 | Threshold Pharmaceuticals (USA - CA) | Cancer - Oncology | |
| 2016-09-28 | SRP-4045 and SRP-4053 | Duchenne muscular dystrophy | 3 | Sarepta Therapeutics (USA - MA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2016-09-28 | Resunab™ (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-Dibenzo(b,d)pyran-9-carboxylic acid | preclinical | Corbus Pharmaceuticals (USA - MA) | Inflammatory diseases | |
| 2016-09-28 | tasquinimod | metastatic castrate-resistant prostate cancer (CRPC) | 3 | Active Biotech (Sweden) Ipsen (France) | Cancer - Oncology |
| 2016-09-28 | Otezla® (apremilast) | plaque psoriasis | 3 | Celgene (USA - NJ) | Autoimmune diseases - Dermatological diseases |
| 2016-09-28 | Otezla® (apremilast) | psoriatic arthritis> | 3 | Celgene (USA - NJ) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-09-27 | CS-3150 (esaxerenone) | essential hypertension | 3 | Daiichi Sankyo (Japan) | Cardiovascular diseases |
| 2016-09-27 | Kyprolis® (carfilzomib) | multiple myeloma | 3 | Amgen (USA - CA) | Cancer - Oncology |
| 2016-09-26 | CA4P (fosbretabulin tromethamine) | platinum-resistant ovarian cancer | 2-3 | Mateon Therapeutics (USA - CA), previously known as Oxigene (USA - CA) | Cancer - Oncology |
